WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation, today announced that management will participate in the Guggenheim Third Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies 2026 London Healthcare Conference. Guggenheim Third Annual Healthcare Innovation Conference Fireside Chat: Tues
Foghorn Therapeutics downgraded to Sell after SMARCA2/Lilly exit; cash runway to 2029 but no catalysts until 2027. Read more on FHTX stock here.
Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.
Foghorn Therapeutics (FHTX) shares fell 29% in Friday trading after Wedbush downgraded the stock to
Foghorn Therapeutics (FHTX) stock slips after Eli Lilly (LLY) ends collaboration, prompting TD Cowen and others to downgrade the company. Read more here.
The companies are scrapping two collaborative cancer programs and don't anticipate any further joint projects
Foghorn Therapeutics (FHTX) has an average rating of overweight and mean price target of $8.86, acco
Foghorn Therapeutics (FHTX) has an average rating of overweight and mean price target of $8.86, acco
Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data. End of Eli Lilly Collaboration and FHD-909 Development Following a review of Phase 1 data for FHD-909 (LY4050784), Foghorn and Eli Lilly & Co. (NYSE:LLY) will not advance the program into clinical development expansion. The companies also will not advance their Selective SMARCA2 degrader program and do not
Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
Foghorn and Lilly will end further collaboration activities after FHD-909 failed to demonstrate sufficient efficacy, while Foghorn cuts its workforce by approximately 40% and extends its cash runway into the second half of 2029. Key Investor TakeawaysFoghorn Therapeutics (NASDAQ:FHTX) and Lilly decided not to advance FHD-909 into clinical expansion following a review of Phase 1 dose-escalation data.
Foghorn and Eli Lilly decided to stop developing FHD-909 after reviewing Phase 1 clinical data.
Foghorn Therapeutics (FHTX) stock plunges as Lilly (LLY) ends a 2021 collaboration resulting in nearly a 40% workforce reduction. Read more here.
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platformPipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass.,
Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.
The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
This is the newest page. Registered accounts read further back.